Results 261 to 270 of about 560,370 (324)

Correction: Tissue-specific properties of type 1 dendritic cells in lung cancer: implications for immunotherapy. [PDF]

J Immunother Cancer
europepmc   +1 more source

Editorial: Tumor-associated tertiary lymphoid structures response during immunotherapy. [PDF]

Front Immunol
Mauldin IS, Minnar CM, Italiano A.
europepmc   +1 more source

Advancing Allogeneic NK Cell Immunotherapy through Microfluidic Gene Delivery

Advanced Science, EarlyView.
The Y‐Hydroporator is a microfluidic gene delivery platform designed for allogeneic NK cell‐based immunotherapies. It achieves highly efficient gene delivery while preserving high cell viability and functionality. By producing engineered NK cells with enhanced cytotoxicity, the platform addresses critical limitations of autologous cell therapy ...
Hyelee Kim, Mujin Lee, Bohwa Han, Jinho Kim, Duck Cho, Junsang Doh, Aram J. Chung   +6 more
wiley   +1 more source

LUNAR: Full Moon or Eclipse? An exploration into tumor treating fields in lung cancer. [PDF]

Transl Oncol
Olivier T, Prasad V.
europepmc   +1 more source

Verteporfin‐Mediated In Situ Nanovaccine Based on Local Conventional‐Dose Hypofractionated Radiotherapy Enhances Antitumor and Immunomodulatory Effect

Advanced Science, EarlyView.
Here gelatinase‐responsive methoxypolyethyleneglycol–PVGLIG–polycaprolactone (mPEG–PVGLIG–PCL) nanoparticles’ loading verteporfin (N@VP) is developed, enhancing radiotherapy via X‐ray‐triggered singlet oxygen generation. Combined with 2 Gy (gray, a radiation dose unit) irradiation, N@VP achieves antitumor efficacy comparable to 8 Gy, and also promotes ...
Zhifan Zhang, Lin Li, Yuchen Ge, Anni Chen, Shanchao Diao, Yueling Yang, Qianyue Chen, Yingling Zhou, Jie Shao, Fanyan Meng, Lixia Yu, Manman Tian, Xiaoping Qian, Zhaoyu Lin, Chen Xie, Baorui Liu, Rutian Li   +16 more
wiley   +1 more source

Therapy related acute myeloid leukemia secondary to CAR-T therapy in refractory/relapsed multiple myeloma patient showing poor prognosis. [PDF]

Ann Hematol
An R, Bao W, Yan Z, Sun H, Xu X, Zhang S.   +5 more
europepmc   +1 more source

PPY‐Induced iCAFs Cultivate an Immunosuppressive Microenvironment in Pancreatic Cancer

Advanced Science, EarlyView.
Pancreatic ductal adenocarcinoma features abundant stromal components that hinder therapy efficacy. Single‐cell RNA sequencing analysis combined with experiments identified PPY, a gastrointestinal hormone, as a novel inducer of immunosuppressive iCAFs. Mechanistic studies revealed that PPY activates the non‐canonical NF‐κB pathway via EGFR.
Mengdie Cao, Wang Peng, Bin Cheng, Ronghua Wang, Wei Chen, Luyao Liu, Hai Huang, Shiru Chen, Haochen Cui, JingWen Liang, Qiaodan Zhou, Si Xiong, Shuya Bai, Luoxia Liu, Yuchong Zhao   +14 more
wiley   +1 more source

Immunotherapy yields breed-specific worst survival outcomes among three investigated therapies in French bulldogs with high-grade glioma. [PDF]

Front Vet Sci
Arnold SA, Taylor AR, Hansen K, Agarwal V, Low WC, Pluhar GE.   +5 more
europepmc   +1 more source

Targeting Splenic Myeloid Cells with Nanobiologics to Prevent Postablative Pancreatic Cancer Recurrence via Inducing Antitumor Peripheral Trained Immunity

Advanced Science, EarlyView.
Using a preclinical pancreatic cancer model, we identified that tumor progression restructures splenic immunity via myeloid cell expansion. MDCa@RBC‐Alipo nanobiologics were engineered to epigenetically and metabolically reprogram splenic myeloid cells, alleviating post‐ablation immunosuppression.
Shengbo Wu, Weichen Xu, Xuexia Shan, Liping Sun, Shuo Liu, Xixi Sun, Shaoyue Li, Xiaodong Hou, Xiaowan Bo, Chengzhong Peng, Bin Huang, Huixiong Xu, Wenwen Yue   +12 more
wiley   +1 more source

Thyroid hormone receptor interacting protein 13 is associated with prognosis and immunotherapy efficacy in human cancers: a pan-cancer analysis. [PDF]

Discov Oncol
Zheng S, Wang H, Wang Y.
europepmc   +1 more source